Skip to main content
Fig. 5 | BMC Pulmonary Medicine

Fig. 5

From: Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

Fig. 5

Change from baseline in inspiratory capacity versus placebo and indacaterol (ITT population). Data reported as LS mean difference ± 95 % CI. ***p < 0.001 vs placebo; p < 0.05 vs indacaterol; ††p < 0.01 vs indacaterol. CI, confidence interval; LS, least squares

Back to article page